Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.2373 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0163 | 0.0589 | 0.0589 |
Loa Loa (eye worm) | hypothetical protein | 0.0163 | 0.0589 | 0.0589 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0 | 0.5 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.121 | 0.5046 | 0.5046 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.121 | 0.5046 | 1 |
Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0163 | 0.0589 | 0.1015 |
Echinococcus granulosus | biogenic amine 5HT receptor | 0.0163 | 0.0589 | 0.1015 |
Echinococcus multilocularis | serotonin receptor | 0.0163 | 0.0589 | 0.1015 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.121 | 0.5046 | 1 |
Leishmania major | C-8 sterol isomerase-like protein | 0.2373 | 1 | 1 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.2373 | 1 | 1 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.121 | 0.5046 | 0.5 |
Brugia malayi | Serotonin receptor | 0.0472 | 0.1905 | 0.1905 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 0.0085 | 0.0085 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.2373 | 1 | 1 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.121 | 0.5046 | 0.5046 |
Echinococcus multilocularis | serotonin receptor | 0.0163 | 0.0589 | 0.1015 |
Loa Loa (eye worm) | hypothetical protein | 0.1213 | 0.506 | 0.506 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0045 | 0.0085 | 0.0085 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.121 | 0.5046 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.